Last reviewed · How we verify

NCT06056882

Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules

Status unknown Last updated 12 February 2024
What this trial tests

trial testing CLE-guided cryobiopsy in Pulmonary Disease in 20 participants. Status unknown.

Timeline
20 September 2023
Primary endpoint
31 March 2024
30 June 2024

Quick facts

Lead sponsorUniversity of Vienna
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment20
Start date20 September 2023
Primary completion31 March 2024
Estimated completion30 June 2024
Sites1 location across Austria

Drugs / interventions tested

Conditions studied

Sponsor

University of Vienna

Who can join

Adults 18 to 100, any sex, with Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is planned to use the CLE probe and cryoprobe simultaneously after detection of the round focus. It is planned to include 5 patients with suspected central airway invading lung carcinoma and 15 patients with suspected peripheral lung carcinoma who have an indication for bronchoscopic histologic confirmation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pulmonary Disease

Currently open trials in the same condition.

Other University of Vienna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06056882.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing